[go: up one dir, main page]

WO2006128740A3 - Anti-vascular methods and therapies employing lysyl oxidase inhibitors - Google Patents

Anti-vascular methods and therapies employing lysyl oxidase inhibitors Download PDF

Info

Publication number
WO2006128740A3
WO2006128740A3 PCT/EP2006/006692 EP2006006692W WO2006128740A3 WO 2006128740 A3 WO2006128740 A3 WO 2006128740A3 EP 2006006692 W EP2006006692 W EP 2006006692W WO 2006128740 A3 WO2006128740 A3 WO 2006128740A3
Authority
WO
WIPO (PCT)
Prior art keywords
lysyl oxidase
oxidase inhibitors
methods
therapies employing
vascular
Prior art date
Application number
PCT/EP2006/006692
Other languages
French (fr)
Other versions
WO2006128740A2 (en
Inventor
Mark Nesbit
Original Assignee
Centelion
Mark Nesbit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centelion, Mark Nesbit filed Critical Centelion
Publication of WO2006128740A2 publication Critical patent/WO2006128740A2/en
Publication of WO2006128740A3 publication Critical patent/WO2006128740A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to pharmaceutical compositions and methods of treating angiogenesis related diseases, such as cancer. Specifically, the invention relates to a composition comprising a lysyl oxidase inhibitor alone or in combination with at least one chemotherapeutic agent, as well as use of the composition and/or combination in the treatment of angiogenesis related disease, such as cancer.
PCT/EP2006/006692 2005-06-02 2006-06-02 Anti-vascular methods and therapies employing lysyl oxidase inhibitors WO2006128740A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68640605P 2005-06-02 2005-06-02
US60/686,406 2005-06-02

Publications (2)

Publication Number Publication Date
WO2006128740A2 WO2006128740A2 (en) 2006-12-07
WO2006128740A3 true WO2006128740A3 (en) 2007-04-12

Family

ID=37482014

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/006692 WO2006128740A2 (en) 2005-06-02 2006-06-02 Anti-vascular methods and therapies employing lysyl oxidase inhibitors

Country Status (1)

Country Link
WO (1) WO2006128740A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168180B2 (en) 2002-11-27 2012-05-01 Technion Research & Development Foundation Ltd. Methods and compositions for modulating angiogenesis
US8927700B2 (en) 2009-08-21 2015-01-06 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US9176139B2 (en) 2007-08-02 2015-11-03 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
CN113321743B (en) * 2021-07-02 2022-10-21 海南精准医疗科技有限公司 Chimeric antigen receptor of targeting lysyl oxidase 1 and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002011667A2 (en) * 2000-08-08 2002-02-14 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
WO2004037992A2 (en) * 2002-10-23 2004-05-06 Exelixis, Inc. Mapk7 as modifier of branching morphogenesis and methods of use
WO2005038465A2 (en) * 2003-10-07 2005-04-28 Centelion Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002011667A2 (en) * 2000-08-08 2002-02-14 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
WO2004037992A2 (en) * 2002-10-23 2004-05-06 Exelixis, Inc. Mapk7 as modifier of branching morphogenesis and methods of use
WO2005038465A2 (en) * 2003-10-07 2005-04-28 Centelion Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GOLDBRUNNER R H ET AL: "MODELS FOR ASSESSMENT OF ANGIOGENESIS IN GLIOMAS", JOURNAL OF NEURO-ONCOLOGY, KLUWER, BOSTON, US, vol. 50, no. 1/2, October 2000 (2000-10-01), pages 53 - 62, XP009035224, ISSN: 0167-594X *
KIRSCHMANN DAWN A ET AL: "A molecular role for lysyl oxidase in breast cancer invasion", CANCER RESEARCH, vol. 62, no. 15, 1 August 2002 (2002-08-01), pages 4478 - 4483, XP002414351, ISSN: 0008-5472 *
KLAUBER N ET AL: "INHIBITION OF ANGIOGENESIS AND BREAST CANCER IN MICE BY THE MICROTUBULE INHIBITORS 2-METHOXYESTRADIOL AND TAXOL", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, no. 1, 1 January 1997 (1997-01-01), pages 81 - 86, XP000982726, ISSN: 0008-5472 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168180B2 (en) 2002-11-27 2012-05-01 Technion Research & Development Foundation Ltd. Methods and compositions for modulating angiogenesis
US9176139B2 (en) 2007-08-02 2015-11-03 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US9289447B2 (en) 2009-01-06 2016-03-22 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US8927700B2 (en) 2009-08-21 2015-01-06 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2

Also Published As

Publication number Publication date
WO2006128740A2 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
WO2007064931A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2007103719A3 (en) MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2007011962A3 (en) Treatment of cancer
WO2008033562A3 (en) Kinase inhibitor compounds
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
WO2007101224A3 (en) Inhibitors of the unfolded protein response and methods for their use
WO2006091395A3 (en) Inhibitors of akt activity
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
MX2007002398A (en) New pharmaceutical compositions for the treatment of cancer.
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2006110638A3 (en) Inhibitors of akt activity
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
WO2010059004A3 (en) Chemical inhibitor of p53-snail binding and pharmaceutical composition for treating cancer disease containing same as its active ingredient
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
WO2006096759A3 (en) Methods and compositions for treating cancer
WO2008125116A3 (en) Upar inhibition
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
AP2413A (en) 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other disease.
WO2006108679A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer
WO2007041614A3 (en) Long acting vegf inhibitors and methods of use
WO2007146335A3 (en) Compounds and compositions for treatment of cancer

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06762498

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06762498

Country of ref document: EP

Kind code of ref document: A2